Elite Pharmaceuticals Inc (QB) (ELTP) News

Elite has a wide open field for generic Vyvanse. As I mentioned recently, for most strengths every generic manufacturer has no product available to order from Cardinal. It’s probably the same at McKesson and AmeriSource Bergen, but I don’t know that for sure.

Yes

https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c

What about Naltrexone? Do you have any stats?

Loaded powder, but can't buy elite cause unsettled funds + penny stock. Such is life...

On the shortage page Elite passed with flying colors again, on the 19th,

https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1

The FDA just loves Nasrat, they keep coming around

As far as Mikah is concerned, WeeZuhl already has a lawyer lined up if Nasrat attempts to sell Elite without full ownership of the Adderalls.

Would be embarrassing for Nasrat to spend his retirement in the courtroom instead of on the beach.

ELTP Catalysts:

X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $4.7 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Final Approval of New Manufacturing Facility/Expansion
__28. Double output of manufacturing and packaging facilities
X 29. Launch approved generic Tylenol with Codeine $47 Million
__30. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__31. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
X 33. Godzilla -Generic Vyvanse Approval $4.3 Billion
__34. Positive BE Study for Concerta CNS Stimulant $1.2 Billion
__35. Godzilla - Generic Vyvance LAUNCH $4.3 Billion
__36. Generic Concerta- FDA submission $1.2 Billion
__37. $100 million in yearly revenues
__38. Generic OxyContin Tentative Approval $720 Million
__39. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__40. Launch generic OxyContin $720 Million
__41. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone - Game Over Drug
__42. Resume R&D on SequestOx Abuse Deterrent Oxycodone
X 43. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
X 44. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024
__45. $200 million in yearly revenue
__46. Patented NDA Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__47. Undisclosed Mikah ANDA(s)
__48. Undisclosed ANDAs/NDAs
__49. Generic Concerta Launch $1.2 Billion
__50. DollarLand PPS
__51. Big Pharma bidding
__52. UpList to the NASDAQ Exchange
__53. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__54. Vegas BABY !!!!!

WHY WHY WHY?
Why do I make the mistake to put you off from ignore every few weeks?

Hi Nas, I recommend that you split the Vyvanse approval and Launch as 2 lines with one checked.

Thanks

What Ive see. happen multiple times is that all options immediately vest upon a M&A transaction, including future options. The future date doesn't need to take arrive before Carter and others cash these in. An acquisition can make that happen sooner. 

CC's are not a requirement. I know one company where the CFO of a publicly held organization that filed the quarterly 10Q's, but only held one live CC per year, the annual. Rest of communication was through PRs. 

As we both know "nasrat said" is not even close to a guarantee !!!!!!!!!!!

I only go by what "nasrat did" .....

How many ANDA's has "nasrat said" would be filed in 2024 ???????????

How many were actually filed ???????????

Hey Thanks A Lot King,

IB_🤴

Upcoming ELTP Catalysts:

Next 1 day-6 months:


X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $4.7 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Positive BE Study for Concerta CNS stimulant
__28. Final Approval of New Manufacturing Facility/Expansion
__29. Double output of manufacturing and packaging facilities
X 30. Launch approved generic Tylenol with Codeine $47 Million
__31. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__32. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__33. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
__34. Godzilla - Generic Vyvanse Approval and Launch $4.7 BILLION
__35. Generic Concerta- FDA submission $1.2 BILLION
__36. $100 million in yearly revenue
__37. Generic OxyContin Tentative Approval $720 Million
__38. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__39. Launch generic OxyContin $720 Million
__40. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone - Drug C in SequestOx reformulation trial -Game Over Drug
__41. Resume R&D on SequestOx Abuse Deterrent Oxycodone
X 42. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
X 43. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024
__44. $200 million in yearly revenue
__45. Undisclosed Mikah ANDA(s)
__46. Undisclosed ANDAs/NDAs
__47. Generic Concerta Approval and Launch

__48. DollarLand PPS
__49. Big Pharma bidding
__50. UpList to the NASDAQ Exchange
__51. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__52. Vegas !!!!!
Bullish

The pps never went to $0.75 that was a mirage.

And here are Carter Ward's options:

3,000,000 shares.

- "Options vest in equal annual increments of 1,000,000 shares on September 5, 2024, September 5, 2025 and September 5, 2026.

Nasrat wants the buyout in early 2027 to be as clean as possible.

So he's letting the Prasco agreement expire without renewal in March 2025 and he's letting the Tagi agreement expire without renewal in August 2025.

What are thoughts on Prasco/Burel relationship ending? Thought this was interesting. Clearly going the way of driving their own exclusive line, noting once again when Tagi's contract is up for renewal next year as well.

I've LITERALLY said that AT LEAST a dozen times on this board.

Now Nasrat COPIES The King because he knows how good it sounds.

LOL! We are "MEGA" - Make Elite Great Again! Hahahahahahahaha

Nasrat has LITERALLY mentioned Nasdaq EVERY single year since 2014 on NEARLY every conference call.

It means absolutely nothing.

He mentioned NASDAQ again.

Great investment in R&D. Nasrat has said they will only develop the big drugs who have $1B+ annual sale. So we should see our pipeline get better and better.

Nasrat promised "at least" two filings by the end of 2024 which means two positive BE studies.

Both BE studies failed.

Now he did say "at least" two filing so maybe the third BE study will actually pass?

Sure would be nice to get another BE or two up to the plate as it can take over a year to get a newly approved BE to market.

So not only is Nasrat hurting Elite with his Mikah nonsense, he's hurting Elite with his warrant nonsense as well.

The reason warrants are recorded as a liability because it shows the fair value loss the company is realizing during the fiscal period by issuing shares at current share price vs the warrant strike price. It's the amount Elite is out of the money on as a gift to Nasrat.

Do you have a learning disability?

They can't FREAKING buy ELTP because their brokerages don't allow it.

Tell everyone you know to tell 10 people to buy $100+ we can start a new MOASS like GME

NOBODY wants stock of another company when Elite gets purchased in 2026 or 2027.

100% CASH.

I invested in Elite, not some other DOUCHEBAG company.

Love it stock and dividend. Love it. Love it love it.

You JUST proved my point and other people's points that are of my same mindset.

OF COURSE Nasrat isn't selling anytime soon for the VERY reason you mentioned!

LMAO!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

The point being the longer a potential buyer waits, revenues increase probability increases our price gets higher!!!!!!!

LMAO.

He can't buy the full 7.5 million shares until January 2026 - OVER a year away.

Like I said, Elite ain't being sold ANY time soon.

It was so obvious and my thoughts are that it will happen after Doug buys those 7 million shares at .03 that are available to him in January.

You're so gullible.

Nasrat's LITERALLY been saying that EVERY SINGLE YEAR since 2014 -- 10 FREAKING YEARS!

In 2017 he PROMISED shareholders that we'd be on the Nasdaq by 2019 AND we'd be in Dollarland by 2019.

“We are in a position that is very attractive for a pharmaceutical company with consistent profits, steady growth and low debt. And we are in a great position, a strong position for merger and acquisition if the price is right or a move up to NASDAQ.”

Read carefully and you will see his priority is the acquisition, not Nasdaq. Don’t be surprised if we have multiple bidders. That and the fact that Carter mentioned be evaluated. A tender offer is based on present and FUTURE revenue.

Charles Schwab.

Fidelity Investments is the best brokerage service by a wide margin.

Nasrat said he's going to conduct a reverse split at the same time of a major news event when uplisting to the Nasdaq in order to avoid the stock tanking right afterwards (because he knows most OTC investors are IDIOTS and think that reverse splits are always bad).

You think Elite will conduct a 10 to 1 reverse split on the launch of Vyvanse since that will be a major news event?

It would perfectly align with the start of the new year since Vyvanse will launch by January 1.

The ONLY problem I see with this scenario is MIKAH is still on the balance sheet and Nasrat will have address this in the February conference call ASSUMING he holds live conference calls again (wouldn't they have to be live since we'd now be on the Nasdaq?)

PS: We could also MERGE with another company to get on the Nasdaq to avoid a reverse split.

Let's see an actual share price target. Maybe in 2025 if we uplist to NASDAQ.

The last BE study PR we got was on Aug 28, 2023 for Vyvanse (during Q2 2024).
From Q3 2024 (starting at Q3 because I can't know if any of Q2 was for Vyvanse studies) forward Elite has spent a total of $7.2M on research and development. Sure would be nice to get another BE or two up to the plate as it can take over a year to get a newly approved BE to market. The first half of calendar year 2025 will be on growing markets of new products, but I expect we will be topping out by end of summer (with that period being reported in Nov 2025). Of course Purdue could give up sometime in the year and that would definitely give us more fuel to continue growth.

Research and development expenses since Vyvanse's successful BE
Q3 2024 1.4M
Q4 2024 6.9M - (1.1M+2.6M+1.4M) = 1.8M
Q1 2025 2.1M
Q2 2025 1.9M

I don't agree that the $0.60 is the value the market gave t use for our current drug line. I believe at $0.60 the market was starting to price in the Vyvance because we didn't hit that until Nov 18th during the conference call. The price was consolidating to the low 0.51 to 0.52 range (ringing up and down to get there of course) until a few minutes into the conference call when it became evident that the Carter and Nasrat were in good moods. It was during that call we learned everything was still going fine. So you are missing a dime off the impact of Vyvance....and that is the impact so far. Remember the mid-Aug call when Nasrat told us of the continuous wave of new products. The market didn't really price that in for a couple of weeks.

Me 2.

I love the guy, and think he's done a great job. His intelligence, and sense of humor are top tier. The MEGA stuff had me dying. 😆

You bet he is.

Is IB still on the MB ?

I was poking fun of the stupid bashers calling him that...tied in with a play on, "Can you smell what the Rock is cooking?" As in...Nasrat has a plan and is executing it very well. If anyone is too daft to either already have or decide to now take a seat at his table, their loss. I've been a long since 2009, dude. Check out my posting history. I knew N2k personally. So....

I can’t stand people calling the ceo the rat. Destiny is ib_

No we don’t. what are you cooking destiny defined?

Correction:
1/2 ownership of the profit split of Adderalls ($2B market) = $0.60

Full ownership of Vyvance ($4.3B) = $0.06 more

Todays price $$0.66

Forward lookin’ Market was well aware that Vyvance was definitely going to get approval first time around due to Nasrats awesome track record with ANDA approvals.

Seed has been planted. Harvest will be here in due time. Our little farma gonna be growing all sorts of greenery for us to feast upon. My seat at the table has already been secured. Can you smell what the "Rat" is cooking? Lol....

2 big catalysts by year end. This should fix it.

Vyvance in extreme shortage has the potential to take a more significant market share since its API supplier is different than all the other competitors .
10-15-20% potentially of a $4.3 B market.
Today’s forward looking Value factored in = $0.06 since approval.

It's half ownership of the profit split, not the mfg revenue. 

1/2 ownership of Adderalls ($2B market) = $0.60

Full ownership of Vyvance ($4.3B) = $0.06 more

Todays price $$0.66

C'mon, man. Reality ain't no fun. 🤪

Companies present non-GAAP metrics all of the time. They have a separate deck and this is what they walk through - results, comparisons, key metrics, forecast, etc. 

You don't exclude it from GAAP reporting to SEC, but you most certainly can report it in a PR and during cc when reviewing financials.

How could they buy 500M shares without spiking the share price?  I don't think that is realistic. 

Not just reddit but some folks here too. Yes I would love to see this stock go higher too, doesn't mean every negative price action is result of so called manipulation....

Really hate to see all these claims of manipulation on reddit about Wall Street boogeymen "manipulators", so sick of all this GME MOASS nonsense on every stock forum like reddit etc. Thinner markets have lower volume and broader swings, it is as simple as that. OTC are pretty much as thin as they get aside from private share groups. I have stock in OTC companies that I can easily see each of my trades when less than 1k trade a day. Some of them are so thinly traded the ticker doesn't even make the correct tape updates because of the minimum update thresholds. There is no conspiracy, just big versus small markets.

A poster on YMB is impersonating Pharma Sleuth. If you check the posting history, you'll figure out who that person is.

I get the impression this will spike by EOM. Waiting for my transfer to complete, hopefully by Friday.